Recent advances in cardiorespiratory medicine: management of pulmonary embolism and prevention of venous thromboembolism, recent treatment strategies in childhood asthma, and dermatological adverse reactions to cardiovascular drugs.
This article is the fifth in a series of CPD articles aimed at reviewing the recent general medical literature relating to topics that may be of interest to dermatologists. This issue looks at advances in cardiorespiratory medicine, including the management of pulmonary embolism and prevention of venous thromboembolism (VT), recent treatment strategies in childhood asthma, and an update on dermatological adverse reactions to cardiovascular drugs.
Finucane
K A
KA
Bristol Dermatology Centre, Bristol Royal Infirmary, Bristol, UK.
Archer
C B
CB
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects; D018927:Anti-Asthmatic Agents / Q000009:adverse effects*; D001249:Asthma / Q000150:complications / Q000188:drug therapy*; D002121:Calcium Channel Blockers / Q000009:adverse effects; D002317:Cardiovascular Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000517:prevention & control*; D006801:Humans; D020108:Nicorandil / Q000009:adverse effects; D011655:Pulmonary Embolism / Q000150:complications / Q000188:drug therapy*; D054556:Venous Thromboembolism / Q000517:prevention & control*
D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D018927:Anti-Asthmatic Agents; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents; D020108:Nicorandil